Ayala Pharmaceuticals’ $25 Million Private Placement

Davis Polk advised the placement agent, Jefferies, in the deal.

Ayala Pharmaceuticals, Inc. executed its $25 million private placement of common stock and warrants to purchase common stock.

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. 

The Davis Polk capital markets team for Jefferies included partner Yasin Keshvargar (Picture) and associate David Li. 

Involved fees earner: Yasin Keshvargar – Davis Polk & Wardwell; David Li – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Jefferies;

Author: Martina Bellini